Population-Based Strategy for Preventing Diabetes and its Complications

Shaw Watanabe, MD, PhD

1Lifescience Promoting Association, Daikyo-cho 25-3-1004, Shinjuku-ku, Tokyo 160-0015, Japan
2Asia Pacific Clinical Nutrition Society (APCNS), Department of Food Science and Nutrition, Zhejiang University, 866 Yu-Hang-Tang Road, Hangzhou 310058, China

*Corresponding author
Shaw Watanabe, MD, PhD
Lifescience Promoting Association, Daikyo-cho 25-3-1004, Shinjuku-ku, Tokyo 160-0015, Japan; Fax: +81-3-5379-7786; E-mail: watashaw@lifescience.or.jp

Article information
Received: March 19th, 2018; Accepted: March 21st, 2018; Published: March 21st, 2018

Cite this article

“PROPER OR NOT” OF INTENSIVE THERAPY

A recent report from the American College of Physicians (ACP) should cause a paradigm change for the treatment of diabetic patients. The main purpose of diabetes therapy is the prevention of complications. The endpoint of many clinical trials is to lower blood glucose levels, but intensive treatments aimed at lowering the HbA1c to less than 6.5% are often accompanied by hypoglycemia as a side effect. At the same time, intensive regimens have not shown a reduction of cardiovascular complications in the long-term. For example, the action to control cardiovascular risk in diabetes (ACCORD) trial was prematurely discontinued, following the observation of an increase in overall mortality, cardiovascular-related deaths, and severe hypoglycemic events. The action in diabetes and vascular disease; preterAx and diamicron-MR controlled evaluation (ADVANCE) study also failed to show a statistically significant clinical benefit, while more adverse effects were seen among those who achieved a median HbA1c level of 6.4%. More intensive treatments with tight glycemic control targets are more costly and associated with increased patient burdens. Only Hollan et al. reported a long-term benefit with intensive therapy in the United Kingdom prospective diabetes study (UKPDS) after 10 years of intervention.

Multidrug intervention trials were also reviewed. The Steno-2 study planned to examine if multifactorial interventions (including behavior interventions) meant to decrease blood glucose, blood pressure and lipids in type-2 diabetes patients, could reduce the risks of microangiopathy, macroangiopathy, and premature deaths. After a median follow-up of 13.3 years, an overall 20% absolute reduction in the risk of death (or decreased hazard ratio of 0.54 for death) was observed in the intensive-therapy group, as compared with the conventional-therapy group.

In the Steno-2 study, however, the number of subjects was small and the average HbA1c percentage also remained at a considerably higher level than the target value in the intensified therapy group. Accordingly, the J-Doit-3 study was planned in Japan, in which 2542 patients were randomly assigned either to ordinary therapy or intensive therapy, and followed-up for a median period of 8.5 years. The goals of the intensive therapy and ordinary therapy were set as follows: HbA1c (<6.2% vs. <6.9%), blood pressure (<120/75 mmHg vs. <130/80 mmHg), LDL cholesterol (<80 mg/dL vs. <120 mg/dL), HDL cholesterol (≥ 40 mg/dL vs. ≥ 40 mg/dL), triacylglycerol (<120 mg/dL vs. <150 mg/dL), BMI (≤22 vs. ≤24), respectively. A primary outcome occurred in 109 patients in the intensive therapy group and in 133 patients in the conventional therapy group (hazard ratio [HR] 0.81, p=0.094). All-cause mortality (HR 1.01, p=0.95) and coronary events (myocardial infarction, coronary artery bypass surgery, and percutaneous transluminal coronary angioplasty; HR 0.86, p=0.44) did not differ between groups, but cerebrovascular events (stroke, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, and carotid artery stenting) were significantly less frequent in the intensive therapy group (HR 0.42, p=0.02). During a median follow-up of 8.5 years, lowered risks of cerebral hemorrhage and nephropathy were observed, but hypoglycemia occurred in 41.1% patients in the intensive treatment vs. 22.3% in the control group.

IDENTIFICATION OF HIGH-RISK DIABETIC PATIENTS FOR INTENSIVE THERAPY

The J-Doit-3 study suggested that multidrug therapy prevented renal insufficiency. Thus, in a public seminar “Challenge to overcome kidney disease”, the Japan Kidney Society and the Japan Diabetes Society jointly recommended that family doctors refer patients to a specialist when diabetic kidney disease is suspected.
Every year in Japan, more than 10,000 patients progress to renal failure and receive hemodialysis as complications of diabetes. The medical cost of treating a total of 300,000 patients with dialysis is expected to exceed 1.5 trillion yen. Prevention of DKD is thus cost-saving public health priority.

Recently, Scandinavian researchers have categorized diabetes mellitus into three severe and two mild forms. Data were consolidated between five cohorts: Swedish All New Diabetics in Scania, Scania Diabetes Registry, All New Diabetics in Uppsala, Diabetes Registry Vaasa, and Malmö Diet and Cancer Cardiovascular Arm. They used six variables for the cluster analysis of 8980 patients, all of whom were newly diagnosed with diabetes between 2008 and 2016. Variables included: the presence of glutamic acid decarboxylase antibody (GADA); age at diagnosis; BMI; HbA1c; homeostatic model assessment 2 (HOMA2) and insulin-resistance (HOMA2-IR), based on C-peptide concentrations.

The analysis revealed the presence of five clusters of diabetes. Cluster 1: Severe autoimmune diabetes (SAID), Cluster 2: Severe insulin-deficient diabetes (SIDD), Cluster 3: Severe insulin-resistant diabetes (SIRD), Cluster 4: Mild obesity-related diabetes (MOD) and Cluster 5: Mild age-related diabetes (MARD). Cluster 2 patients had substantially higher HbA1c levels and diabetic retinopathy was more common than in other clusters. Patients in cluster 3 had a substantially higher risk of end-stage renal disease. Such a clinically useful stratification is an important step towards tailor-made precision medicine in diabetes. A low-protein diet is effective to reverse the progression to kidney failure, and low-protein rice is easily available to decrease protein from diet.

The ACP has proposed that the treatment of diabetes for the older person aged more than 80 years should primarily be adjusted to their quality of life (QOL). The American Diabetes Association (ADA) guidelines of 2017 raise psychosocial issues in a number of areas, including the self-management of diabetes and the management of co-morbid conditions. Doctors should become familiar with existential therapy or holistic treatment, among techniques that can achieve behavioral changes in patients.

**Dietary Intervention as a Population Strategy**

The cross-sectional study on dietary habit and health (GENKI study) clarified the characteristics of obese people and brown rice eaters among 6000 participants. Obese people have lifestyle-related diseases, such as diabetes, hypertension, hyperlipidemia, gout, bronchitis and gallstones, and they typically take medications for these diseases with an increased odds ratio (OR) between 2 and 3. They felt unhealthy and lost vivid feeling in daily life. They spent a sedentary life, preferring fatty foods and meat, to vegetables, and ate until full stomach.

On the contrary, brown rice eaters consume significantly more carrots, green yellow vegetables, radish, ginger, burdock, lotus root, sweet potatoes, yam, salty plum pickles (umeboshi), sesame, peanut, chestnut, mushroom, dried mushroom (shiitake), dried radish, dried seaweed (norì), kelp (konbu), red bean (azuki), and soy milk. They did not consume meat, but soy protein was substituted to meat and fish. They felt healthy and vivid, became better compared to the previous year, and showed low OR for lifestyle-related diseases (OR=around 0.3).

It has been clarified in recent studies, that brown rice contains functional ingredients, such as dietary fibres, ferulic acids, GABA, and antioxidants. They keep a good balance of the bacterial flora and of the immune system. Considering that obesity is associated with various diseases, it is important to consider brown rice among interventions to control obesity.
REFERENCES


Watanabe S


